MEXIDOL® Sequential Therapy of Patients With Primary Open-angle Glaucoma (POAG)
Status:
COMPLETED
Trial end date:
2024-02-02
Target enrollment:
Participant gender:
Summary
Hypothesis: The use of neurocytoprotectors helps restore the functional activity of mitochondria, improve the nervous activity of the retina and optic nerve, and stabilize the glaucomatous process.